[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 9, Issue 2 (12-2023) ::
Caspian J Reprod Med 2023, 9(2): 9-14 Back to browse issues page
Comparing Mifepristone with Misoprostol combination to Misoprostol alone for labour induction in antepartum stillbirth
Bhallamudi Venkata Alekhya , Usha Yadav * , Shashi Lata Kabra , Soma Mitra , Monika Suri Grover
1Department of Obstetrics & Gynaecology, Deen Dayal Upadhyay Hospital, New Delhi, India , drusha.yadav98@gmail.com
Abstract:   (723 Views)
Background: Despite the advancement in thanatological research, stillbirth remains one of the most proscribed and misunderstood types of losses. Aim of our study was to compare the efficacy and safety of the combination of mifepristone and Misoprostol vs. Misoprostol alone for the induction of labor in antepartum stillbirth.
Methods: This study recruited fifty-two pregnant individuals at a gestational age beyond 28 weeks who had been diagnosed with antepartum stillbirth. Participants allocated to group I received an oral dose of 200 mg of Mifepristone. Subsequently, after a 24-hour interval, patients were administered 50 mcg of Misoprostol orally every 4 hours, up to a maximum of four doses. In contrast, participants in group II were provided with a placebo of Tablet Calcium (500mg). Following the same 24-hour interval, they received a dose of 50 mcg of Misoprostol orally every 4 hours, for a maximum of four doses.
Results: The mean (standard deviation) induction-to-delivery interval (IDI) in group I and group II were 8.6 (1.9) and 11.9 (3.7) hours, respectively (p <0.001). In group I, the mean (SD) total dosage of Misoprostol was 65.4 (30.9) milligrams, whereas in group II, it was 126.9 (45.2) milligrams. A significant difference was observed between the two groups in terms of the total dosage of Misoprostol (p <0.001).
Conclusion: These results underscore the potential benefits of Mifepristone and Misoprostol in improving outcomes for individuals experiencing antepartum stillbirth. Further research is warranted to validate and expand upon these findings, with the ultimate goal of enhancing care and support for those affected by stillbirth.
Keywords: Mifepristone, Misoprostol, Stillbirth
Full-Text [PDF 389 kb]   (196 Downloads)    
Type of Study: Original Research | Subject: Obstetrics and Gynecology
Received: 2023/10/23 | Accepted: 2023/12/20 | Published: 2023/12/27
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Alekhya B V, Yadav U, Kabra S L, Mitra S, Grover M S. Comparing Mifepristone with Misoprostol combination to Misoprostol alone for labour induction in antepartum stillbirth. Caspian J Reprod Med 2023; 9 (2) :9-14
URL: http://caspjrm.ir/article-1-225-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 9, Issue 2 (12-2023) Back to browse issues page
Caspian Journal of Reproductive Medicine
Caspian J Repord Med: Infertility and Reproductive Health Research Center of Babol University of Medical Sciences, Babol-Amol old highway, after Mohammadhasan Khan bridge, Babol, Mazandaran, Iran, P.O. Box: 47135-547 Tel: +98-11-32274881-2 Fax: +98-11-32274880 E-mail: info@caspjrm.ir Website: www.caspjrm.ir
Persian site map - English site map - Created in 0.05 seconds with 36 queries by YEKTAWEB 4657